Thyroid Tablet Recall Now Class I: What Patients Need to Know About the Vitruvias Recall

Updated: September 24, 2026

If you take a natural thyroid medication, check your bottle today. A recall that Vitruvias Therapeutics announced in August now sits at the FDA's most serious risk level, and the affected lot expires on September 30, just days from now. One thing matters more than anything else in this story: don't stop your medicine without calling your doctor first.

We're covering this because recall notices are easy to miss, and a medicine you take every day is the last thing you expect to be the problem. Health news also spreads fast online, and not all of it is accurate, so every fact in this article links directly to the FDA or the news report it came from. If this helps even one person check their bottle in time, it's worth writing.

What happened?

On August 21, 2026, Alabama-based Vitruvias Therapeutics announced a voluntary nationwide recall of one lot of its Thyroid Tablets, USP 30 mg, after testing confirmed the tablets could be superpotent. The FDA posted the company's announcement on August 24.

The FDA has since classified the recall as Class I, the highest of its three risk levels, with a classification date of September 22.

What does a Class I recall mean?

According to the FDA's official definitions, a Class I recall is a situation where there is a reasonable probability that using the product will cause serious adverse health consequences or death. By comparison, Class II covers temporary or medically reversible effects, and Class III covers products unlikely to cause harm.

In plain terms, the FDA has judged this to be a serious risk. It does not mean every tablet in the lot has been confirmed to be harmful, but it does mean the risk is serious enough that nobody taking it should ignore the recall.

Which product is affected?

Only one lot is part of this recall. Per the recall notice:

Thyroid, USP is a natural preparation made from pig (porcine) thyroid glands. It contains levothyroxine and liothyronine and is used to treat hypothyroidism, or an underactive thyroid.

Why is a superpotent thyroid pill a risk?

The company's risk statement says a stronger-than-labeled dose can cause hyperthyroidism (an overactive thyroid). Possible symptoms include, but are not limited to:

• Weight loss and heat intolerance
• Fatigue, nervousness and muscle weakness
• High blood pressure and chest pain
• Rapid heart rate or heart rhythm disturbances

The company says the elderly, pregnant women and infants face greater risk, especially over longer periods. Excess thyroid hormone in older adults has been linked to adverse outcomes, particularly for heart health. Overtreatment during pregnancy is associated with complications including premature delivery and low birth weight, and in infants it may affect growth and development.

As of the August announcement, Vitruvias said it had not received any reports of adverse events related to this recall.

What should you do?

1. Check your bottle. Look for the lot number 504950 and NDC 69680-166-00 on the label. If you're unsure, ask your pharmacist.
2. Do not stop taking it on your own. The recall notice advises patients to contact their healthcare provider for guidance or a replacement prescription first.
3. Talk to your doctor if you've had any problems that may be related to the medication, such as a racing heart, chest pain or unexplained weight loss.
4. Contact the company with questions at safety@vitruvias.com or (256) 239-9373, Monday to Friday, 9 a.m. to 5 p.m. CT.
5. Report side effects to the FDA through its MedWatch reporting program, or call 1-800-332-1088 to request a form.

Taking a different brand? Here's how to be sure

This recall covers only the single Vitruvias lot listed above. It does not cover other brands, other strengths or other lots. To check for other recalls, see the FDA's official recalls page.